Company intelligence / Profile preview

Debiovision

Montreal, Quebec, Canadadebiopharm.com ↗

Ownership: Private
Development stage: Other

Overview

Sanvar™ (vapreotide acetate), a synthetic peptide targeting SSTR2/SSTR5, was submitted to the FDA and received an approvable letter in December 2004. It was approved in Mexico for esophageal/gastric varices. Two fully human monoclonal antibodies, SC‑1 and PAM‑1, were also under development for oncology indications at the time of acquisition.

Therapeutic areas: GastroenterologyOncology
Modalities: Synthetic peptideMonoclonal antibody
Industry: Biotech

Partnerships

Managed through parent group

Beyond the preview

Go deeper on Debiovision.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Debiovision.

Explore the full profile